Safety Alert Novel Oral Anticoagulants (NOACs) Issue Apixaban (Eliquis®), dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) are anticoagulants licensed in varying doses in adults for prevention and treatment of venous - Apixaban - Document - PDFSEARCH.IO

First Page	Meta Content
	Safety Alert Novel Oral Anticoagulants (NOACs) Issue Apixaban (Eliquis®), dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) are anticoagulants licensed in varying doses in adults for prevention and treatment of venous Add to Reading List Document Date: 2015-05-07 16:55:49 Open Document File Size: 111,49 KB Share Result on Facebook Company COX / / / Facility Tallaght Hospital / Beaumont Hospital / / IndustryTerm prevention of coronary heart disease / healthcare professionals / / MedicalCondition non-valvular atrial fibrillation / venous thromboembolism / atrial fibrillation / coronary heart disease / infection / acute kidney injury / thrombosis / chronic renal impairment / Stroke / sepsis / / MedicalTreatment alternative therapy / medication errors / concomitant therapy / counselling / / Organization Health Products Regulatory Agency / Tallaght Hospital / State Claims Agency / Beaumont Hospital / / Product clopidogrel / ibuprofen / / URL www.hpra.ie / www.medicines.ie / www.imsn.ie / / SocialTag Anticoagulants Ketones Bristol-Myers Squibb Hematology Dabigatran Warfarin Rivaroxaban Apixaban Stroke Chemistry

Safety Alert Novel Oral Anticoagulants (NOACs) Issue Apixaban (Eliquis®), dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) are anticoagulants licensed in varying doses in adults for prevention and treatment of venous Add to Reading List